newsfilter.io

Jeff Low

Showing 1–3 of 3 transcripts.

  1. a16z27 min

    a16z Podcast | Shifting Risk Mindsets, From Tech to Bio

    Vijay Pande, Jorge Conde, Jeff Low, Jeffrey Lowe

    This event guides tech founders through the critical challenges of translating their innovations into the biotechnology sector, emphasizing the necessity of treating biotech firms as data-driven enterprises. It details strategies to avoid operational pitfalls like "death by a thousand pilots" and outlines structural frameworks, such as LLC ring-fencing, to protect platform value while developing proprietary assets. Furthermore, the session provides actionable insights on diagnostics reimbursement, early validation "kill tests," and aligning hybrid investor syndicates to ensure sustainable growth in a high-barrier market.

  2. a16z19 min

    a16z Podcast | Scaling Healthcare

    Sean Duffy, Rajeev Singh, Jeff Low

    Driven by the rising global burden of preventable chronic diseases, self-insured employers are pivoting from cost-shifting strategies to outcomes-based programs like Omada Health that utilize machine learning and personalized coaching to reduce claims. By integrating digital interventions as billable medical benefits and adopting revenue models tied to specific patient metrics, these initiatives have demonstrated the ability to generate 5% to 7% annual cost savings while improving workforce productivity and talent retention. This shift is further enabled by regulatory advancements, such as new CPT codes and lower thresholds for self-insurance, which allow organizations of 200 or more employees to proactively manage metabolic conditions before they escalate into expensive chronic diagnoses.

  3. a16z27 min

    Shifting Risk Mindsets, from Tech to Bio

    Jorge Conde, Vijay Pande, Jeff Low, Jeffrey Lowe

    Bio-hybrid startups face critical challenges in translating novel technologies to traditional biological partners and avoiding the "death by a thousand pilots" trap through strategic deal structures. Founders must carefully position their platforms to capture value in high-impact areas like Phase III failure prediction while isolating asset risks via legal separation to prevent resource drain. Successful execution requires a hybrid approach to funding and partnership, where founders bridge the linguistic gap between tech and bio communities to align reimbursement models with long-term investor expectations.